Association of PD-L1 expression with prognosis among patients with 10 select cancers
Torben Steiniche(Aarhus University), Kai‐Li Liaw(United States Military Academy), Morten Ladekarl(Aalborg University Hospital), Michael Busch-Sørensen(Center for Clinical & Basic Research), Wei Zhou(Broad Institute), Andrew K. Joe(Merck & Co., Inc., Rahway, NJ, USA (United States)), Simon Andreasen(Zealand University Hospital), Scott K. Pruitt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jeanette Bæhr Georgsen(Aarhus University Hospital)
Cited by 1
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer
|Nature Communications|2021|386